• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种具有强免疫原性和持续病毒学抑制作用的治疗性乙型肝炎信使核糖核酸疫苗。

A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.

作者信息

Zhao Huajun, Shao Xianyu, Yu Yating, Huang Lulu, Amor Narh Philip, Guo Kun, Weng Changzhen, Zhao Weijun, Yang Ailu, Hu Jiesen, Yang Hongbao, Liu Zhenguang, Han Qiuju, Shi Leilei, Sun Shiyu, Zhang Jian, Lin Ang, Yang Yong

机构信息

Institute of Immunopharmaceutical Sciences, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.

Vaccine Center, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

出版信息

NPJ Vaccines. 2024 Feb 3;9(1):22. doi: 10.1038/s41541-024-00813-3.

DOI:10.1038/s41541-024-00813-3
PMID:38310094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10838333/
Abstract

Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.

摘要

在此，我们报告一种用于慢性乙型肝炎（CHB）治疗的mRNA疫苗的研发及全面评估。在通过病毒载体介导的HBV转染产生的两种不同的HBV携带小鼠模型（pAAV-HBV1.2和rAAV8-HBV1.3）中，该疫苗表现出足够且持久的病毒学抑制作用，以及在诱导强烈的先天免疫激活、高水平病毒特异性抗体、记忆B细胞和T细胞方面强大的免疫原性。因此，mRNA平台在开发对抗CHB的治疗性疫苗方面具有前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/495f585a5934/41541_2024_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/495f585a5934/41541_2024_813_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b690/10838333/c80d48472fda/41541_2024_813_Fig2_HTML.jpg

相似文献

1
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.一种具有强免疫原性和持续病毒学抑制作用的治疗性乙型肝炎信使核糖核酸疫苗。
NPJ Vaccines. 2024 Feb 3;9(1):22. doi: 10.1038/s41541-024-00813-3.
2
The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model.载有 HBV 基因组的质粒剂量对水动力注射小鼠模型中 HBV 的持续存在有很大影响。
Virol J. 2017 Oct 25;14(1):205. doi: 10.1186/s12985-017-0874-6.
3
The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.质粒骨架的剂量在决定 hydrodynamic injection 小鼠模型中的 HBV 清除中起着重要作用。
Virol J. 2018 May 21;15(1):89. doi: 10.1186/s12985-018-1002-y.
4
HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice.HBV X 蛋白治疗性疫苗通过动员单核细胞浸润肝脏加速 HBV 携带者小鼠中病毒抗原的清除。
J Biomed Sci. 2020 May 28;27(1):70. doi: 10.1186/s12929-020-00662-x.
5
Efficient stabilization of therapeutic hepatitis B vaccine components by amino-acid formulation maintains its potential to break immune tolerance.通过氨基酸配方有效稳定治疗性乙肝疫苗成分可保持其打破免疫耐受的潜力。
JHEP Rep. 2022 Oct 13;5(2):100603. doi: 10.1016/j.jhepr.2022.100603. eCollection 2023 Feb.
6
A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.基于高度减毒水疱性口炎病毒的疫苗平台控制乙型肝炎病毒在乙型肝炎小鼠模型中的复制。
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01586-18. Print 2019 Mar 1.
7
A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA.一种携带乙型肝炎病毒共价闭合环状 DNA 的新型小鼠模型。
Cell Mol Gastroenterol Hepatol. 2022;13(4):1001-1017. doi: 10.1016/j.jcmgh.2021.11.011. Epub 2021 Dec 9.
8
Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.在水动力注射小鼠模型中，聚肌胞苷酸（Poly(I:C)）治疗可导致乙型肝炎病毒通过干扰素依赖性方式清除。
J Virol. 2014 Sep;88(18):10421-31. doi: 10.1128/JVI.00996-14. Epub 2014 Jun 11.
9
Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.在初次免疫期间激活 CD4 T 细胞决定了治疗性乙型肝炎疫苗在乙肝携带者小鼠模型中的成功。
J Hepatol. 2023 Apr;78(4):717-730. doi: 10.1016/j.jhep.2022.12.013. Epub 2023 Jan 9.
10
Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B.在含有新型乙型肝炎病毒（HBV）基因型 B 克隆的水动力注射小鼠模型中，HBx 基因沉默抑制 HBV 基因表达和复制。
Virol J. 2013 Jun 28;10:214. doi: 10.1186/1743-422X-10-214.

引用本文的文献

1
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.乙型、丙型和丁型肝炎的发病机制、预防及治疗进展
Virol J. 2025 Aug 11;22(1):274. doi: 10.1186/s12985-025-02907-3.
2
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies.实现乙肝表面抗原血清学清除的新兴疗法：聚焦新型联合策略。
Hepatol Int. 2025 Jun 11. doi: 10.1007/s12072-025-10828-0.
3
Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.基于mRNA的几种肝炎病毒疫苗的最新进展

本文引用的文献

1
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.一种基于 mRNA 的四价季节性流感疫苗（mRNA-1010）在健康成年人中进行的 1/2 期随机临床试验的安全性和免疫原性：中期分析。
Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7.
2
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞。
Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10.
3
Algorithm for optimized mRNA design improves stability and immunogenicity.
Biol Proced Online. 2025 Jun 3;27(1):20. doi: 10.1186/s12575-025-00269-2.
4
Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy.利用信使核糖核酸平台开发针对鸡蛋过敏的疫苗。
Vaccines (Basel). 2025 Apr 24;13(5):448. doi: 10.3390/vaccines13050448.
5
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用：从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
6
A Multivalent mRNA Therapeutic Vaccine Exhibits Breakthroughs in Immune Tolerance and Virological Suppression of HBV by Stably Presenting the Pre-S Antigen on the Cell Membrane.一种多价mRNA治疗性疫苗通过在细胞膜上稳定呈现前S抗原，在乙肝病毒的免疫耐受和病毒学抑制方面取得突破。
Pharmaceutics. 2025 Feb 7;17(2):211. doi: 10.3390/pharmaceutics17020211.
7
Current and emerging strategies for the prevention of hepatocellular carcinoma.预防肝细胞癌的当前及新出现的策略
Nat Rev Gastroenterol Hepatol. 2025 Mar;22(3):173-190. doi: 10.1038/s41575-024-01021-z. Epub 2024 Dec 9.
8
mRNA vaccines for infectious diseases - advances, challenges and opportunities.传染病的 mRNA 疫苗：进展、挑战与机遇。
Nat Rev Drug Discov. 2024 Nov;23(11):838-861. doi: 10.1038/s41573-024-01042-y. Epub 2024 Oct 4.
9
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends.mRNA疫苗在肿瘤靶向治疗中的作用机制、临床应用及发展趋势
Biomark Res. 2024 Aug 31;12(1):93. doi: 10.1186/s40364-024-00644-3.
10
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems.mRNA疫苗的最新进展：从靶点选择到递送系统
Vaccines (Basel). 2024 Aug 1;12(8):873. doi: 10.3390/vaccines12080873.
优化 mRNA 设计的算法可提高稳定性和免疫原性。
Nature. 2023 Sep;621(7978):396-403. doi: 10.1038/s41586-023-06127-z. Epub 2023 May 2.
4
Discovery of a first-in-class orally available HBV cccDNA inhibitor.发现一种一流的口服可用乙肝cccDNA抑制剂。
J Hepatol. 2023 Apr;78(4):742-753. doi: 10.1016/j.jhep.2022.12.014. Epub 2022 Dec 30.
5
Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction.树突状细胞内胆固醇蓄积逆转慢性乙型肝炎病毒感染诱导的功能障碍。
Cell Mol Immunol. 2022 Dec;19(12):1347-1360. doi: 10.1038/s41423-022-00939-1. Epub 2022 Nov 11.
6
Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.工程化抗 PDL1 与 IFNα 靶向肝脏中的免疫抑制和激活信号，打破 HBV 免疫耐受。
Gut. 2023 Aug;72(8):1544-1554. doi: 10.1136/gutjnl-2022-327059. Epub 2022 Oct 31.
7
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine.先天免疫和适应性免疫对辉瑞-生物科技 BNT162b2 疫苗的作用机制。
Nat Immunol. 2022 Apr;23(4):543-555. doi: 10.1038/s41590-022-01163-9. Epub 2022 Mar 14.
8
A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity.一种具有有利生物分布模式和有前景免疫效果的核壳结构 COVID-19 mRNA 疫苗。
Signal Transduct Target Ther. 2021 May 31;6(1):213. doi: 10.1038/s41392-021-00634-z.
9
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.三抗原乙型肝炎疫苗与单抗原乙型肝炎疫苗在成人中的免疫原性和安全性（PROTECT）：一项随机、双盲、III 期临床试验。
Lancet Infect Dis. 2021 Sep;21(9):1271-1281. doi: 10.1016/S1473-3099(20)30780-5. Epub 2021 May 11.
10
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.一项评估 RSV 预融合 F 蛋白 mRNA 疫苗在健康年轻和老年成年人中的安全性和免疫原性的 1 期、随机、安慰剂对照研究。
Hum Vaccin Immunother. 2021 May 4;17(5):1248-1261. doi: 10.1080/21645515.2020.1829899. Epub 2020 Oct 29.